N
Nikolas von Bubnoff
Researcher at University of Freiburg
Publications - 127
Citations - 3533
Nikolas von Bubnoff is an academic researcher from University of Freiburg. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 99 publications receiving 2213 citations. Previous affiliations of Nikolas von Bubnoff include Sapienza University of Rome & University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele,Johan Richter,Joelle Guilhot,Franz Gruber,Henrik Hjorth-Hansen,Antonio Almeida,Jeroen Janssen,Jiri Mayer,Perttu Koskenvesa,Panayiotis Panayiotidis,Ulla Olsson-Strömberg,Joaquin Martinez-Lopez,Philippe Rousselot,Hanne Vestergaard,Hans Ehrencrona,Veli Kairisto,Katerina Machova Polakova,Martin Müller,Satu Mustjoki,Marc G. Berger,Alice Fabarius,Wolf-Karsten Hofmann,Andreas Hochhaus,Markus Pfirrmann,Francois-Xavier Mahon,Gert J. Ossenkoppele,Maria Pagoni,Stina Söderlund,Martine Escoffre-Barbe,Gabriel Etienne,Jolanta Dengler,Françoise Huguet,Nikolas von Bubnoff,Hana Klamova,Edgar Faber,François Guilhot,Kourosh Lotfi,Delphine Rea,Tim H. Brümmendorf,Gorgine E. de Greef,Leif Stenke,Franck E. Nicolini,Laurence Legros,Andreas Burchert,Jaroslava Voglová,Aude Charbonnier,Emmanuel Gyan,Volker Kunzmann,Peter E. Westerweel +48 more
TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.
Journal ArticleDOI
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser,Nikolas von Bubnoff,Jason Butler,Mohamad Mohty,Dietger Niederwieser,Reuven Or,Jeff Szer,Eva Maria Wagner,Tsila Zuckerman,Bruyère Mahuzier,Judith Xu,Celine Wilke,Kunal K. Gandhi,Gérard Socié +13 more
TL;DR: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy.
Journal ArticleDOI
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Silvia Spoerl,Nimitha R. Mathew,Michael Bscheider,Annette Schmitt-Graeff,Sophia Chen,Tony A. Mueller,Mareike Verbeek,Julius C. Fischer,Vera Otten,Martina Schmickl,Kristina Maas-Bauer,Jürgen Finke,Christian Peschel,Justus Duyster,Hendrik Poeck,Robert Zeiser,Nikolas von Bubnoff +16 more
TL;DR: Ruxolitinib represents a novel targeted approach in GVHD by suppression of proinflammatory signaling that mediates tissue damage and by promotion of tolerogenic Treg cells.
Journal ArticleDOI
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nimitha R. Mathew,Nimitha R. Mathew,Francis Baumgartner,Lukas Braun,David O’Sullivan,Simone Thomas,Miguel Waterhouse,Tony Andreas Müller,Kathrin Hanke,Kathrin Hanke,Sanaz Taromi,Petya Apostolova,Anna Lena Illert,Wolfgang Melchinger,Sandra Duquesne,Annette Schmitt-Graeff,Lena Osswald,Kai-Li Yan,Arnim Weber,Sonia Tugues,Sabine Spath,Dietmar Pfeifer,Marie Follo,Rainer Claus,Michael Lübbert,Christoph Rummelt,Hartmut Bertz,Ralph Wäsch,Johanna Haag,Andrea Schmidts,Michael Schultheiss,Dominik Bettinger,Robert Thimme,Evelyn Ullrich,Yakup Tanriver,Giang Lam Vuong,Renate Arnold,Philipp Hemmati,Dominik Wolf,Markus Ditschkowski,Cordula A. Jilg,Konrad Wilhelm,C. Leiber,Sabine Gerull,Jörg Halter,Claudia Lengerke,Thomas Pabst,Thomas Schroeder,Guido Kobbe,Wolf Rösler,Soroush Doostkam,Stephan Meckel,Kathleen Stabla,Kathleen Stabla,S K Metzelder,S K Metzelder,Sebastian Halbach,Tilman Brummer,Zehan Hu,Zehan Hu,Joern Dengjel,Joern Dengjel,Björn Hackanson,Christoph Schmid,Udo Holtick,Christof Scheid,Alexandros Spyridonidis,Friedrich Stölzel,Rainer Ordemann,Lutz P. Müller,Flore Sicre-de-Fontbrune,Gabriele Ihorst,Jürgen Kuball,Jan E. Ehlert,Daniel Feger,Eva-Maria Wagner,Jean-Yves Cahn,Jacqueline Schnell,Florian Kuchenbauer,Donald Bunjes,Ronjon Chakraverty,Simon Richardson,Saar Gill,Nicolaus Kröger,Francis Ayuk,Luca Vago,Fabio Ciceri,Antonia M.S. Müller,Takeshi Kondo,Takanori Teshima,Susan Klaeger,Susan Klaeger,Bernhard Kuster,Dennis Dong Hwan Kim,Daniel J. Weisdorf,Walter J.F.M. van der Velden,Daniela Dörfel,Wolfgang Bethge,Inken Hilgendorf,Andreas Hochhaus,Geoffroy Andrieux,Melanie Börries,Hauke Busch,John M. Magenau,Pavan Reddy,Myriam Labopin,Joseph H. Antin,Andrea S. Henden,Andrea S. Henden,Geoffrey R. Hill,Geoffrey R. Hill,Glen A Kennedy,Merav Bar,Anita Sarma,Donal P. McLornan,Ghulam J. Mufti,Betul Oran,Katayoun Rezvani,Omid Shah,Robert S. Negrin,Arnon Nagler,Marco Prinz,Marco Prinz,Andreas Burchert,Andreas Neubauer,Andreas Neubauer,Dietrich W. Beelen,Andreas Mackensen,Nikolas von Bubnoff,Wolfgang Herr,Burkhard Becher,Gérard Socié,Michael A. Caligiuri,Eliana Ruggiero,Chiara Bonini,Georg Häcker,Justus Duyster,Jürgen Finke,Erika L. Pearce,Bruce R. Blazar,Robert Zeiser,Robert Zeiser +141 more
TL;DR: Findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7–IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans.
Journal ArticleDOI
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
TL;DR: It is shown that the sensitivity of EGFR mutations toward different inhibitors varies significantly, thus establishing a comprehensive sensitivity profile for each inhibitor, and the identification of comprehensive drug resistance profiles opens the opportunity to test alternative EGFR inhibitors in vitro.